WILLOWBROOK, Ill., April 9, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that centhaquine, a drug in final stage of development, can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome (ARDS), reduce multiple organ dysfunction score (MODS) and decrease mortality in patients with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Pharmazz has completed a multi-centric, double-blind, randomized, placebo-controlled phase 3 study to assess the efficacy of centhaquine as a resuscitative agent to be used as an adjuvant to standard treatment in hypovolemic shock patients. In a trial conducted in 105 patients, centhaquine produced statistically significant improvement in both ARDS and MODS and reduced 28-day all-cause mortality. Safety of centhaquine has been established in multiple clinical trials conducted in 180 human subjects.
Centhaquine acts through a unique mechanism of action. It increases blood pressure and cardiac output by augmenting venous blood return to the heart (venous alpha2B-adrenergic receptor stimulation). Centhaquine is likely to attenuate a decrease in venous return to the heart and prevent life-threatening hypotension, which occurs in about 30% of patients following endotracheal intubation and/or positive pressure ventilation. Centhaquine may reduce ventilator time, prevent patients from worsening towards necessity for an extracorporeal membrane oxygenation (ECMO) and improve survival. Pharmazz is approaching various regulatory agencies regarding use of centhaquine as an adjuvant in the management of critically ill patients with COVID-19. Since therapeutic options for this life-threatening condition are limited, centhaquine may be considered for compassionate or emergency use, and may fulfil the unmet need for serious, life-threatening condition of COVID-19 during this pandemic outbreak.
Company has also filed a patent application on the composition and use of centhaquine for the treatment of critically ill COVID-19 patients and patients with ARDS. The company further announces issuance of Brazilian Patent Number PI 1013903-6 titled "Novel Therapeutic Treatments Using Centhaquin" dated March 3, 2019.
About Pharmazz, Inc. Pharmazz, Inc. is a privately held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.
Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.
ContactPharmazz, Inc. Shruti Gulati[email protected]
Advertisement
Pharmazz has completed a multi-centric, double-blind, randomized, placebo-controlled phase 3 study to assess the efficacy of centhaquine as a resuscitative agent to be used as an adjuvant to standard treatment in hypovolemic shock patients. In a trial conducted in 105 patients, centhaquine produced statistically significant improvement in both ARDS and MODS and reduced 28-day all-cause mortality. Safety of centhaquine has been established in multiple clinical trials conducted in 180 human subjects.
Advertisement
Centhaquine acts through a unique mechanism of action. It increases blood pressure and cardiac output by augmenting venous blood return to the heart (venous alpha2B-adrenergic receptor stimulation). Centhaquine is likely to attenuate a decrease in venous return to the heart and prevent life-threatening hypotension, which occurs in about 30% of patients following endotracheal intubation and/or positive pressure ventilation. Centhaquine may reduce ventilator time, prevent patients from worsening towards necessity for an extracorporeal membrane oxygenation (ECMO) and improve survival. Pharmazz is approaching various regulatory agencies regarding use of centhaquine as an adjuvant in the management of critically ill patients with COVID-19. Since therapeutic options for this life-threatening condition are limited, centhaquine may be considered for compassionate or emergency use, and may fulfil the unmet need for serious, life-threatening condition of COVID-19 during this pandemic outbreak.
Company has also filed a patent application on the composition and use of centhaquine for the treatment of critically ill COVID-19 patients and patients with ARDS. The company further announces issuance of Brazilian Patent Number PI 1013903-6 titled "Novel Therapeutic Treatments Using Centhaquin" dated March 3, 2019.
About Pharmazz, Inc. Pharmazz, Inc. is a privately held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.
Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.
ContactPharmazz, Inc. Shruti Gulati[email protected]
View original content:http://www.prnewswire.com/news-releases/centhaquine-can-provide-hemodynamic-stability-improve-tissue-oxygenation-reduce-pulmonary-edema-acute-respiratory-distress-syndrome-ards-multiple-organ-dysfunction-score-mods-and-mortality-in-coronavirus-disease-2019-covi-301038562.html
SOURCE Pharmazz, Inc.
